Average Ratings 0 Ratings
Average Ratings 0 Ratings
Description
We combine clinical and experimental data through machine learning techniques to explore human disease biology and promote the development of precision medicine. Our innovative Contingent AI™ technology comprehends the intricate relationships present in the data, yielding advanced insights. To combat data bias, we refine our machine learning models based on decisions made during the pre-processing and feature engineering phases. We utilize zebrafish, cellular, and various phenotypic animal models to test and confirm in silico predictions through in vivo experiments, along with genetic modifications conducted both in vitro and in vivo to enhance translation. By employing active learning and computer vision on validated models that focus on cardiac, central nervous system, and rare disorders, we swiftly integrate new data into our machine learning frameworks, allowing for continuous improvement and adaptation in our methodologies. This iterative process not only enhances the accuracy of our predictions but also enables us to stay at the forefront of research in precision medicine.
Description
Pharmaceutical companies require extensive genomic data to effectively implement precision medicine initiatives; however, they frequently rely on merely 10% of the available information for their decisions. Genomenon provides access to the complete dataset. Their Prodigy™ Patient Landscapes offer a streamlined and economical solution for natural history research, aiding the creation of therapies for rare diseases by deepening understanding of both retrospective and prospective health data. Utilizing an advanced AI-driven methodology, Genomenon conducts a thorough evaluation of each patient documented in the medical literature in a significantly reduced timeframe. Ensure you capture all relevant insights by exploring every genomic biomarker featured in published studies. Each scientific claim is substantiated by concrete evidence drawn from the medical literature, allowing researchers to uncover all genetic drivers and identify variants recognized as pathogenic in accordance with ACMG clinical standards, thereby enhancing the development process of targeted therapies. By leveraging this comprehensive approach, pharma companies can enhance their research effectiveness and ultimately improve patient outcomes.
API Access
Has API
No
API Access
Has API
Yes
Integrations
Google Cloud Platform
No
Pricing Details
No price information available.
Free Trial
No
Free Version
No
Pricing Details
No price information available.
Free Trial
No
Free Version
No
Deployment
Web-Based
Yes
On-Premises
No
iPhone App
No
iPad App
No
Android App
No
Windows
No
Mac
No
Linux
No
Chromebook
No
Deployment
Web-Based
Yes
On-Premises
No
iPhone App
No
iPad App
No
Android App
No
Windows
No
Mac
No
Linux
No
Chromebook
No
Customer Support
Business Hours
No
Live Rep (24/7)
No
Online Support
Yes
Customer Support
Business Hours
Yes
Live Rep (24/7)
No
Online Support
Yes
Types of Training
Training Docs
No
Webinars
No
Live Training (Online)
No
In Person
No
Types of Training
Training Docs
Yes
Webinars
Yes
Live Training (Online)
Yes
In Person
Yes
Vendor Details
Company Name
BioSymetrics
Country
United States
Website
www.biosymetrics.com/platform
Vendor Details
Company Name
Genomenon
Country
United States
Website
www.genomenon.com/pharma/